David Shaw’s Citius Pharmaceuticals CTXR Stock Holding History

David Shaw’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,166	Closed	-$188K	–	5009
2021 Q2	$188K	Buy	+2,166	New	+$130K	﹤0.01%	4458

Other funds holding CTXR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

David Shaw's CTXR Position: Q3 2021 in Review

David Shaw sold out of Citius Pharmaceuticals (CTXR) in Q3 2021, closing a stake of 2,166 shares — an estimated $188K sold.

David Shaw first reported a position in CTXR in Q2 2021 and held it in 1 quarter. The position peaked at $188K in Q2 2021. 71 funds tracked by Wall St. Rank hold CTXR as of Q3 2021.

David Shaw reported no remaining Citius Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
David Shaw sold 2,166 Citius Pharmaceuticals shares in Q3 2021, an estimated $188K.
David Shaw first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 1 quarter.
David Shaw's Citius Pharmaceuticals position peaked at $188K in Q2 2021.
71 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.